When was Sanguine founded?

Sanguine was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Sanguine located?

Sanguine is headquartered in Los Angeles, United States. It is registered at Sherman Oaks, California.

How many employees does Sanguine have?

As of Jul 31, 2026, the latest employee count at Sanguine is 100.

Is Sanguine a funded company?

Sanguine is a funded company, having raised a total of $5.53M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 22, 2013.

When was the latest funding round of Sanguine?

Sanguine's latest funding was a $***** Conventional Debt round on Oct 31, 2023, with participation from 1 investor. Its primary sector is Data as a Service. In United States, the Data as a Service sector has seen $732M in funding in 2026 to date.

Where does Sanguine rank among its competitors?

Sanguine ranks 23rd amongst 368 active competitors, of which 61 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Tempus, which secured $460M in Jul, 2026.

Who are the top competitors of Sanguine?

Sanguine's top competitors include Medidata, Verily and IQVIA. Among them, Tempus secured the most recent funding round in July, 2026.

Sanguine - 2026 Company Profile, Team, Funding & Competitors

Company Details

Building a databank of patient-derived data for advanced research. The company engages patients in biomedical research by delivering transparency throughout the research process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen, and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery with leading academic laboratories and companies, such as Vertex.

Website: www.sanguinebio.com
Social
Email ID: *****@sanguinebio.com
Registered Address: Sherman Oaks, California

Key Metrics

Founded Year

2010

Location

Los Angeles, United States

Stage

Series B

Total Funding

$5.53M in 6 rounds

Latest Funding Round

Conventional Debt, Oct 31, 2023, $*****

Investors

Broadoak Capital Partners & 10 more

Ranked

23^rd among 368 active competitors

Employee Count

100 as on Jul 31, 2026

Similar Companies

Medidata & 431 more

View Sanguine's full profile

Sanguine is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SANGUINE BIOSCIENCES, INC CIN: 272874274 , United States, Active	Dec 31, 2009	-	89 (As on Dec 31, 2024)	-

Sanguine has raised a total funding of $5.53M over 6 rounds. Its first funding round was on Feb 22, 2013. Its latest funding round was a Conventional Debt round on Oct 31, 2023 for $*****. 1 investor participated in its latest round. Sanguine has 11 institutional investors.

Here is the list of recent funding rounds of Sanguine:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2023	2974384	Conventional Debt	9295285	9083067	9829287	8187031
Jan 09, 2023	7171453	Series B	2663750	1569947	8436115	2699266
Feb 01, 2019	2078064	Grant (prize money)	7770366	8121044	3064136	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Sanguine's funding rounds and investors

The founders of Sanguine is Brian Neman.

Here are the details of Sanguine's key team members:

Brian Neman: Co-founder, Chief Operating Officer of Sanguine. They serve on the board of 1 company.
Contact Info: 1 email address

Sanguine's Board of Directors

Sanguine's board has 4 active members. Brian Neman, Randy Socol, Tim Triche and Rudiger Hausherr are independent board members.

Here is the list of Sanguine's board of directors:

Name	Type	Representing	Status	Duration
Brian Neman	Independent board member	-	Current	11y 9m
draqzxx	Independent board member	-	Current	7y 2m
wcpnyck	Independent board member	-	Current	3y 6m
wordgwf	Independent board member	-	Current	2y 2m

View details of Sanguine's Founder profiles and Board Members

Sanguine's employee count trend

Sanguine has 100 employees as of Jul 26. Here is Sanguine's employee count trend over the years:

Uncover Sanguine's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sanguine include Medidata, Verily and IQVIA. Here is the list of Top 10 competitors of Sanguine, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Medidata 1999, New York City (United States), Acquired	AI-based clinical trial management software for researchers	$41.5M	Insight Partners, TFS & 11 others	86/100
2nd	Verily 2015, Dallas (United States), Series D	A data platform and technology company purpose-built to power AI-enabled precision health	$2.8B	Silver Lake, Temasek & 9 others	82/100
3rd	IQVIA 1982, Durham (United States), Public	Provider of clinical research and commercialization solutions for healthcare	$1.74M	Leonard Green and Partners, Aisling Capital ... & 12 others	80/100
4th	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	77/100
5th	Signant Health 2000, Plymouth Meeting (United States), Acquired	Provider of a software solution for clinical trial management	$3.4M	Harvest Partners, 3i Group & 4 others	72/100
6th	Science 37 2014, Los Angeles (United States), Acquired	Provider of a suite solution for clinical trials for researchers	$106M	Redmile Group, Lux Capital & 12 others	70/100
7th	TriNetX 2013, Cambridge (United States), Acquired	Provider of clinical trial management software for researchers and professionals	$102M	Merck Global Health Innovation Fund, F2 Ventures ... & 6 others	66/100
8th	Wcg Clinical 2012, Princeton (United States), Acquired	CRO offering regulatory and ethical review services for clinical research	-	Ares Capital Corporation, Prospect Capital ... & 6 others	64/100
9th	Obvio Health 2015, Orlando (United States), Series B	Provider of clinical trials design and recruitment platform	$66M	Dedalus Group, Guardant Health & 13 others	62/100
10th	Autonomize 2021, Austin (United States), Series A	AI-based drug discovery tool for researchers	$32M	Cigna Ventures, Tau Ventures & 8 others	61/100
23rd	Sanguine 2010, Los Angeles (United States), Series B	Building a databank of patient-derived data for advanced research	$5.53M	FCVC, Catalio Capital Management & 9 others	55/100